Table 1.

Response made to freedom of information request made by Hereditory Angioedema (HAE)-UK to 40 Primary Care Trusts (PCT) Clusters in response to the questions: (a) ‘Does your PCT Cluster have a commissioning policy for overall management of HAE’. (b) ‘Does your PCT Cluster have an overall commissioning policy for C1 esterase inhibitor’. (c) ‘Does your PCT Cluster have an overall commissioning policy for icatibant’. (d) ‘Does your PCT Cluster have an overall policy for home use of C1 esterase inhibitor’. (e) ‘Does your PCT Cluster have an overall policy for home use of C1 esterase inhibitor’. Data provided by Ann Price, HAE-UK 57

Commissioning policy	No	Yes	Mixed	Unknown
(a) Overall management of HAE	34	3	3	0
(b) C1INH concentrate	31	7	2	0
(c) Icatibant	31	8	1	0
(d) Home use C1INH concentrate	35	0	3	2
(e) Home use icatibant	34	1	3	2